Back to Journals » OncoTargets and Therapy » Volume 11

Long non-coding RNA FENDRR inhibits cell proliferation and is associated with good prognosis in breast cancer

Authors Li Y, Zhang W, Liu P, Xu Y, Tang L, Chen W, Guan X

Received 19 August 2017

Accepted for publication 4 October 2017

Published 14 March 2018 Volume 2018:11 Pages 1403—1412

DOI https://doi.org/10.2147/OTT.S149511

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Giandomenico Roviello

Peer reviewer comments 3

Editor who approved publication: Dr Ingrid Espinoza


Yan Li,1 Wenwen Zhang,2 Pengying Liu,1 Yumei Xu,1 Lin Tang,3 Weiwei Chen,3 Xiaoxiang Guan1,3

1Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern Medical University, Guangzhou, 2Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 3Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China

Introduction: FENDRR is a long non-coding RNA (lncRNA) that mediates the modification of the epigenetic landscape of target promoters by binding to polycomb repressive complex 2. However, the role of FENDRR in breast cancer remains unknown.
Materials and methods: We detected the expression of FENDRR in 52 breast cancer patients’ tissues and five breast cancer cell lines. The association between FENDRR expression and clinicopathological features and prognosis of breast cancer patients was also analyzed. Moreover, cell proliferation assays, flow cytometry analysis, wound-healing assays, and transwell migration assays were performed to detect the biological effects of FENDRR in the breast cancer cells. A xenograft model was used to explore the role of FENDRR expression on tumor growth.
Results: We found that FENDRR expression was lower in breast cancer cell lines and cancerous tissues than in the adjacent normal tissues. Low expression of FENDRR was associated with a shorter overall survival and a shorter progression-free survival in breast cancer patients (p<0.001, p<0.001, respectively). We found that FENDRR inhibits breast cancer cell proliferation and migration and promotes cell apoptosis, while FENDRR knockdown promotes breast cancer cell proliferation and migration and suppresses cell apoptosis. Finally, we also detected that FENDRR overexpression could inhibit tumor growth in a xenograft model.
Conclusion: Our data suggested that FENDRR inhibits breast cancer cell proliferation, pro­motes cell apoptosis, and is associated with good prognosis in breast cancer. Thus, FENDRR plays an important role in the growth and progression of breast cancer.

Keywords: breast cancer, FENDRR, lncRNA, prognosis, proliferation
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]